Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BFRI
BFRI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BFRI News
Biofrontera to Report 2025 Financial Results on March 19
17h ago
Newsfilter
Biofrontera Announces Ameluz® Clinical Trial Results
1d ago
Newsfilter
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
1d ago
moomoo
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
1d ago
moomoo
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
1d ago
moomoo
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
1d ago
moomoo
Biofrontera Wins Patent Review Against Sun Pharma
Feb 26 2026
Newsfilter
Biofrontera Completes Phase 1 Pharmacokinetics Study for Ameluz®
Feb 17 2026
Newsfilter
BIOFRONTERA INC ANTICIPATES SUPPLEMENTAL NDA FILING FOR EXTREMITY, NECK, AND TRUNK INDICATION IN Q3 2026
Feb 17 2026
moomoo
BIOFRONTERA INC. REPORTS COMPLETION OF DATABASE LOCK FOR PHASE 1 PHARMACOKINETICS STUDY OF AMELUZ® IN TREATING ACTINIC KERATOSES ON TRUNK AND EXTREMITIES
Feb 17 2026
moomoo
Biofrontera's Ameluz® sNDA Accepted by FDA for sBCC Treatment
Feb 11 2026
Newsfilter
BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026
Feb 11 2026
moomoo
BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
Feb 11 2026
moomoo
Biofrontera Reports Positive Phase 3 Trial Results for Ameluz PDT
Feb 09 2026
NASDAQ.COM
Biofrontera's Ameluz® Clinical Trial Shows Significant Success
Feb 09 2026
Newsfilter
Biofrontera Reports Record Q4 Revenue of $17.5 Million, Driven by Ameluz® Sales
Jan 13 2026
Globenewswire
Show More News
